Michael A. Thompson, MD, Oncology, Milwaukee, WI

Michael A.ThompsonMDPhD, FASCO

Oncology Milwaukee, WI

Hematologic Oncology

Co-Director, Oncology Precision Medicine, Advocate Aurora Health

See the full profile

Dr. Thompson is on Doximity
As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Thompson's full profileAlready have an account?

Office Address

  • Vince Lombardi Cancer Clinic at Aurora St. Luke’s Medical Center
    2900 W. Oklahoma Avenue
    Milwaukee, WI 53215
    Phone
    (414) 649-6380

    Fax
    (414) 649-5389

  • Is this information wrong?

Education & Training

  • University of Texas MD Anderson Cancer CenterUniversity of Texas MD Anderson Cancer CenterFellowship
  • Mayo School of Graduate Medical EducationMayo School of Graduate Medical EducationResidency
  • Mayo School of Graduate Medical EducationMayo School of Graduate Medical EducationInternship
  • Mayo Graduate School (MD/PhD Program)OtherTraining
  • Mayo Clinic School of MedicineMayo Clinic School of MedicineMedicalSchool
  • University of Wisconsin at MadisonOtherTraining

Certifications & Licensure

  • WI State Medical LicenseWI State Medical License 2007 - 2021
  • TX State Medical LicenseTX State Medical License 2004 - 2014
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Clinical Trials Research Award Aurora Research Institute, 2014
  • ASCO Leadership Development Program American Society of Clinical Oncology (ASCO), 2012
  • "Man of the Year" Nominee, SE Wisconsin Leukemia & Lymphoma Society (LLS), 2012
  • 14 more in this section...Join now to see the full profile

Clinical Trials

Publications & Presentations

  • Journal Articles
  • How can social media improve oncology care?  Thompson, MA, Community Oncology, 7/2013
  • Rabbit lung indolethylamine N-methyltransferase three–dimensional structure prediction: a model approach to bridge sequence to function in pharmacogenomic studies.  Thompson MA, Weinshilboum RM, El Yazal J, Wood TC, Pang Y-P, J Mol Model.
  • Denileukin diftitox activity in relapsed and refractory B-cell non-Hodgkin's lymphoma.  Thompson MA and Dang NH, Am J Oncol Rev
  • 1 more in this section...Join now to see the full profile
  • Lectures
  • ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in relapsed/refractory multiple myeloma (RRMM) with asses... 2019 ASCO Annual Meeting - 6/1/2019
  • Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study 2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Reportable actionability versus pragmatic actionability: Implementing precision medicine at three large health systems. 2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Other
  • Indolethylamine N-Methyltransferase (INMT): Structural and Functional Studies Thompson MA
    Mayo Clinic
  • Oncology iPhone Applications: Perspectives From a Researcher/Community-Based Hematologist/Oncologist and a Physician Reviewer of Medical Apps. Thompson MA and Misra S, Oncology. 2012; 26(3):1-2
    http://www.cancernetwork.com/practice/content/article/10165/2044783
  • Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma Li C, Thompson MA, Tamayo AT, Zuo Z, Li C, Lee J, Vega F, Ford RJ, Pham LV, Oncotarget
    http://www.impactjournals.com/oncotarget

Press Mentions

  • Clinical Trial Mythbusters: Does the Clinical Trial Process Need an Extreme Makeover?July 09, 2018
  • Session at ASCO Shows Community Oncology Success in Precision MedicineJune 03, 2018
  • What Is the State of Precision Medicine for Myeloma?March 15, 2018

Committees

  • Co-Chair, VIA Oncology Medical Oncology Indolent Lymphoma Committee 2015 - Present
  • Member, ASCO Cancer Education Committee on Lymphoma & Plasma Cell Disorders 2014 - Present
  • Member, ECOG-ACRIN NCORP Advisory Committee 2014 - Present
  • Member, ASCO Cancer Research Committee (CRC) 2013 - Present
  • CRF Council, ASCO Community Research Forum (CRF) Committee 2013 - Present
  • Member, ECOG-ACRIN Myeloma Core Committee 2009 - Present
  • Member, Conquer Cancer Foundation (CCF) Annual Giving Development Committee 2013 - 2014
  • Member, ASCO Integrated Media & Technology (IMT) / Education Committee 2010 - 2013